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Abstract
Background: Understanding cell signaling pathways that contribute to metastatic colon cancer is critical to risk
stratification in the era of personalized therapeutics. Here, we dissect the unique involvement of mitogenic
pathways in a TGFβ or activin-induced metastatic phenotype of colon cancer.
Method: Mitogenic signaling/growth factor receptor status and p21 localization were correlated in primary colon
cancers and intestinal tumors from either AOM/DSS treated ACVR2A (activin receptor 2) −/− or wild type mice.
Colon cancer cell lines (+/− SMAD4) were interrogated for ligand-induced PI3K and MEK/ERK pathway activation
and downstream protein/phospho-isoform expression/association after knockdown and pharmacologic inhibition
of pathway members. EMT was assessed using epithelial/mesenchymal markers and migration assays.
Results: In primary colon cancers, loss of nuclear p21 correlated with upstream activation of activin/PI3K while
nuclear p21 expression was associated with TGFβ/MEK/ERK pathway activation. Activin, but not TGFβ, led to PI3K
activation via interaction of ACVR1B and p85 independent of SMAD4, resulting in p21 downregulation. In contrast,
TGFβ increased p21 via MEK/ERK pathway through a SMAD4-dependent mechanism. While activin induced EMT via
PI3K, TGFβ induced EMT via MEK/ERK activation. In vivo, loss of ACVR2A resulted in loss of pAkt, consistent with
activin-dependent PI3K signaling.
Conclusion: Although activin and TGFβ share growth suppressive SMAD signaling in colon cancer, they diverge in
their SMAD4-independent pro-migratory signaling utilizing distinct mitogenic signaling pathways that affect EMT.
p21 localization in colon cancer may determine a dominant activin versus TGFβ ligand signaling phenotype
warranting further validation as a therapeutic biomarker prior to targeting TGFβ family receptors.
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Introduction
Colon cancer remains the second deadliest cancer in
the United States with an estimated 136,830 new cases
and 50,310 deaths in 2014 [1]. The overall incidence, as
well as cancer-related mortality, have both decreased
over the past 10 years, which has been attributed to
enhanced screening and early detection. However, once
colon cancer has metastasized, the five year survival
remains poor [1]. Further, and disturbingly, the number
of young patients with metastatic disease is increasing
[1]. Understanding the switch to metastatic behavior and
developing therapeutic strategies to target metastatic
signaling are key unmet clinical challenges. This un-
derstanding will lead to the generation of functional
biomarkers to better predict patient risk and potential
treatment response to individual pathway inhibition.
Recent efforts in cancer genome comprehensive
sequencing have confirmed key genes whose muta-
tions can drive tumorigenesis [2] and have solidified
components of the Transforming Growth Factor (TGF) β
superfamily as drivers of pathogenesis in colon cancer.
These include inactivating mutations in the TGFβII
receptor (TGFBR2), the activin receptor 2A (ACVR2A)
and downstream signaling molecule SMAD4 [2]. TGFβ
and activin are involved in the regulation of cell prolif-
eration, differentiation, migration and apoptosis [3–5].
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Activin and TGFβ utilize a specific type I/type II
receptor complex for signal transduction [6–8]. In
the canonical pathway, ligand binding leads to activation
of SMAD2/3/4 proteins, translocation to the nucleus and
transcriptional regulation of target genes to affect growth
suppression and p21 upregulation. The non-canonical
signaling pathway is SMAD4-independent and may
engage other signaling pathways [4, 5]. Activin and
TGFβ both have dual and opposing roles in colon
carcinogenesis as they may promote growth suppres-
sion, as well as migration and metastasis in more
advanced colon cancer, also known as the molecular
switch [9–12]. TGFβ itself has opposing functions: in
early stage colon cancer, the TGFβ super family is growth
suppressive, while in advanced disease, high TGFβ serum
and stroma levels are associated with poor prognosis
[13, 14]. Similarly, high levels of plasma activin in pan-
creatic cancer patients are significantly associated with
decreased overall survival and increased distant metas-
tases [15]. Therefore, it is critical to understand the
switch from growth suppression to proliferation for
TGFβ and activin signaling. In order to identify targets
which may directly affect metastatic behavior, we need
to understand how the respective pathways intersect
with other signaling cascades and how specifically,
activin and TGFβ differ in their effects.
We have previously shown that in colon cancer cells,
the cyclin dependent kinase (CDK) inhibitor p21 is a
downstream target of both activin and TGFβ [9]. In
primary colon cancer tumors, we observed that nuclear
p21 localization correlated with TGFBR2 expression
while loss of nuclear p21 is associated with ACVR2A
expression, respectively [9]. To understand the contri-
bution of each signaling pathway to the net signaling
measured in tumor samples, we further dissected acti-
vin and TGFβ signaling in colon cancer cells. Despite
shared SMAD2/3/4 signaling of activin and TGFβ, we
observed opposing downstream effects on p21; namely
TGFβ induces SMAD-dependent upregulation of p21,
whereas activin leads to SMAD-independent downregula-
tion of p21 via increased proteasomal degradation [9].
Additionally, since SMAD4 by itself is frequently
mutated and inactivated in colon cancer [16], it is
important to understand the SMAD-independent sig-
naling of activin and TGFβ and the downstream
impact on metastatic processes.
While TGFβ induced EMT in cancer has been studied
in detail, there are only a few conflicting reports on
activin and EMT [17, 18]. TGFβ has been shown to
induce an invasive phenotype and EMT [17, 19, 20],
but the precise mechanism is not well described. Acti-
vin’s effects on EMT have not been studied in detail to
date. Reports in the literature indicate that increased
expression of pAKT is associated with the loss of p21
expression in adenoid cystic carcinomas [21] while
ligand activation of TGFBR2 can activate the MEK/ERK
pathway [5]. In colon cancer, the influence of mitogenic
signaling on the regulation of EMT and the effect on a
metastatic phenotype in colon cancer through TGFβ is
not well known. However, previous reports have impli-
cated PI3K signaling in EMT following TNF ligand stimu-
lation in colon cells [22]. Phosphatidylinositol-3’-kinase
(PI3K) signaling is involved in the regulation of several
key cellular processes such as cell growth, survival, motil-
ity and proliferation which are involved in tumorigenesis
[23]. The PI3K pathway plays a prominent role in many
cancers; in colon cancer specifically, upstream activa-
tion or gain of function mutations are common [24].
Akt, one of the downstream effectors of PI3K signaling,
regulates apoptosis and cell cycle progression. Activa-
tion of the PI3K/Akt pathway can arise through various
mechanisms and is associated with a poor prognosis in a
number of cancers [24]. MEK/ERK mitogenic signaling is
also commonly activated in tumors and affects regulation
of the cell cycle as well as senescence [25]. ERK may
directly influence p21 localization and stability [25], but
the effects of TGFβ/activin–mediated mitogenic signaling
have not been studied.
In order to delineate the respective and unique
contributions of activin and TGFβ in anticipation of
individual pathway inhibition in metastatic signaling,
we first interrogated the association of PI3K/Akt and
MEK/ERK signaling with the status of activin and TGFβ
receptor expression in colon cancer patients. Then, we
further dissected downstream use of mitogenic signaling
pathways in activin and TGFβ-specific signaling as well as
effects on p21 regulation, EMT, and migration in colon
cancer. Better understanding of the distinct effects of
activin and TGFβ signaling in metastatic disease is
crucial in anticipation of specific pathway inhibition
via small molecules. Moreover, we suggest nuclear p21
as a potential therapeutic biomarker that may accurately
distinguish whether activin or TGFβ signaling is dominant
in a given colon cancer patient. This study adds to the
growing complexity of preclinical information neces-
sary to plan much needed trials in advanced colon
cancer disease using pathology-guided therapeutics.
Results
Loss of nuclear p21 is indicative of activin/pAkt
activation, while nuclear p21 is associated with TGFβ/
pERK activation in primary colon cancer tissues
We have previously observed that loss of nuclear p21
expression correlates with either presence of ACVR2A
or absence of TGFBR2 in primary colon cancers [9].
Here we have expanded those observations through
assessing the relative expression of ACVR2A/TGFBR2
receptors compared to paired normal tissue through
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immunohistochemistry in 110 primary colon cancer
tumors and examined the impact of receptor status
on p21 localization and activation of pAkt and pERK
mitogenic signaling pathways (Fig. 1 and Table 1).
Increased nuclear p21 was associated with TGFBR2
expression (Additional file 1: Table S2) and TGFBR2 ex-
pression correlated with an increase in pERK (p = 0.0019,
Table 1A) which is consistent with a TGFβ/pERK/nuclear
p21 axis. Loss of nuclear p21 was associated with
ACVR2A expression (Additional file 1: Table S2) and
an increase in pAkt expression (p = 0.001, Table 1B).
In line with our hypothesis, pERK and pAkt expres-
sion were not associated with each other (p = 1). This
suggests that nuclear p21 expression may be used as an
indicator of net upstream TGFβ or activin mitogenic sig-
naling, or more functionally, TGFβ/SMAD growth
suppressive, versus activin/migratory signaling, which
would aid in planning inhibition with small mole-
cules. Statistical analysis of nuclear p21 versus TGFBR2
expression and loss of nuclear p21 versus ACVR2A
expression showed no significant differences. While there
was a trend towards correlation of ACVR2A expres-
sion and loss of p21 in advanced stages the relatively
small sample size and predominance of stage III
cases limited this analysis. To further understand the
distinct individual regulation of activin and TGFβ in
colon cancer, we next dissected pathway components
in colon cancers cells in vitro.
TKApKREpp21 ACVR2TGFBR2
expression
loss
p21 loss
ACVR2 - ACVR2 +
pAkt - pAkt +
p21 nuclear 
TGFBR2 - TGFBR2 +
pERK - pERK+
    primary
colon cancers
TGFBR2 -TGFBR2 +
110
11
9
A
B
61 49
6451
442
38
293 12
Fig. 1 Loss of nuclear p21 is indicative of activin/pAkt activation, while nuclear p21 is associated with TGFβ/pERK activation in primary colon
cancer tissues. In human colon cancer tissue, loss of nuclear p21 is associated with ACVR2A/pAkt expression while nuclear p21 is associated
with TGFBR2/pERK expression. A total of 110 primary human colon cancer tissues were stained for ACVR2A/TGFBR2/p21/pERK/pAkt expression
and pathway expression associations were determined. a Representative colon cancer tissues showing nuclear (p21/pERK) or cytosolic (TGFBR2/
ACVR2A/pAkt) expression (upper panel) versus loss (lower panel). b Schematic of colon cancer signaling pathways based on signal component
staining. Dominant pathways with p21 expression as diverging point drawn in red (p21 loss/ACVR2A+/pAkt + and p21 expression/TGFBR2+/pERK+,
respectively). For statistical analysis, see Table 1
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Activin, but not TGFβ, utilizes PI3K/Akt to downregulate
p21 in a SMAD4-independent manner
We previously demonstrated that activin downregulates
p21 independently of SMAD4 [9], a key downstream
signaling component of both the activin and TGFβ path-
ways. As PI3K/Akt signaling is a known regulator of p21 in
cancer [26], to elucidate the SMAD4-independent sig-
naling of activin in colon cancer, we hypothesized that
the activin receptor directly engages the PI3K/Akt
pathway upstream of SMAD4. To test this hypothesis,
we assessed whether activin and/or TGFβ led to PI3K
activation via primary receptor association with the p85
regulatory subunit of PI3K and the subsequent down-
stream increase in phosphorylation of Akt in SMAD4
wild type and null colon cancer cell lines.
Using ACVR2A/TGFBR2 wild type FET colon cancer
cells, FET with SMAD4 knockdown, and the SMAD4-null
colon cancer cell line SW480, we found a SMAD4-
independent increase in pAkt Ser473 after activin treat-
ment compared to control and TGFβ treatment (Fig. 2a).
Conversely, pAkt Thr308 did not change (data not shown)
consistent with phosphorylation through the mTOR/
rictor pathway and not the ER stress pathway [27].
While ACVR1B and p85 co-localized following acti-
vin treatment in ACVR2A/TGFBR2 wild type FET cells
(Fig. 2b), TGFβ treatment did not increase basal levels
of p85/TGFBR1 interaction (Fig. 2b). These data were
confirmed in FET SMAD4 knock down cells and
SW480 cells (data not shown), indicating a SMAD4-
independent process. To assess the interaction of p85
with other activin/TGFβ receptor isoforms, we co-
immunoprecipitated p85 with ACVR2A, TGFBR1, and
TGFBR2 and determined that ACVR1B has the highest
affinity for p85. The interaction between ACVR2A and
p85 was less than the interaction between ACVR1B
and p85. (Additional file 2: Figure S1), and there was
no interaction between TGFBR1 or TGFBR2 and p85
(Additional file 2: Figure S1). Therefore, we conclude
that stimulation by activin ligand leads to a relative
dominance of the interaction of p85 with ACVR1B
(which is specific for activin signaling) over the less
specific ACVR2A.
To determine if the activin-stimulated interaction of
ACVR1B and p85 results in activation of the PI3K
pathway, we knocked down the two most common
Akt isoforms (Akt1/2) and assessed p21 expression.
In the FET cells, the activin-induced downregulation
of p21 was abrogated following Akt1/2 knockdown
(Fig. 2c), however, Akt1/2 knockdown had no effect
on p21 expression after TGFβ treatment. This implies
that activin-induced downregulation of p21 involves
ACVR1B interaction with p85 to activate PI3K/Akt
signaling. In contrast, TGFβ-mediated upregulation of
p21 does not utilize PI3K signaling.
TGFβ, but not activin, stabilizes p21 via SMAD4 and MEK/
ERK
To further dissect the relevant downstream pathways
of TGFβ and activin-induced regulation of p21, we
utilized FET, FET with SMAD4 knockdown, and SMAD4-
null SW480 and treated with pharmacologic inhibitors of
PI3K (LY 290042) or MEK (U0126) prior to ligand treat-
ment. Expression of p21 was then measured by immuno-
blotting. Inhibition of PI3K blocked the activin-induced
downregulation of p21 expression regardless of SMAD4
status (Fig. 3a, left panels), whereas TGFβ induction of
p21 was dependent on both MEK/ERK and SMAD4
(Fig. 3a, right panels). These results indicate that TGFβ-
induced upregulation of p21 engages the MEK/ERK
pathway, while activin-induced p21 downregulation is
unaffected by MEK/ERK. To simultaneously quantify
the impact of ligand treatment (TGFβ or activin versus
untreated control) on pERK1/2 and ppERK1/2 isoforms,
we employed isoelectric point immunoassay analysis. We
observed an increase of pERK1/2 and ppERK1/2 isoforms
after TGFβ treatment compared to both control and
activin treatment (Fig. 3b) confirming that TGFβ, but not
activin, induces the MEK/ERK signaling. Further, we
found that pSMAD2 induction following TGFβ was
dependent on MEK/ERK (Fig. 3c). The inhibitors alone
do not have an effect on p21 and pSMAD2 expression
(data not shown). Therefore, in colon cancer cells,
TGFβ stabilizes p21 via MEK/ERK in a SMAD4-
dependent manner resulting in upregulation of p21.
Activin and TGFβ use distinct mitogenic signaling to
affect SMAD4- independent migration
Activin and TGFβ are both inducers of migration [9, 10]
and mitogenic signaling is associated with a migratory
phenotype [24]. To determine if TGFβ- and activin-in-
duced migration involves MEK/ERK or PI3K signaling
respectively, we inhibited PI3K or MEK in our colon
cancer cell models and assessed the impact on
Table 1 Correlation of signaling pathway expression in primary
colon cancer slides
A) pERK and TGFBR2 are correlated with a p = 0.0019 (Fisher’s exact test)
TGFBR2+ TGFBR2- total p = 0.0019
pERK + 41 22 63
pERK - 16 31 47
total 57 53 110
B) pAKT and ACVR2 are correlated with a p = 0.0001 (Fisher’s exact test)
ACVR2+ ACVR2- total p = 0.0001
pAkt + 44 16 60
pAkt - 18 32 50
total 62 48 110
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migration following ligand stimulation. Activin-induced
migration decreased significantly following inhibition
of PI3K irrespective of SMAD4 status and was not
affected by MEK inhibitors. However, TGFβ-induced
migration was significantly decreased after MEK inhibition,
independently of SMAD4 expression, and was not affected
by PI3K inhibition (Fig. 4, Additional file 3: Figure S2).
These data suggest that the migration induced by TGFβ
and activin is independent of SMAD4 and employs distinct
mitogenic signaling.
Activin and TGFβ induce epithelial to mesenchymal
transition via distinct mitogenic signaling pathways
Consistent with a role in oncogenic signaling, TGFβ has
been shown to induce epithelial to mesenchymal transi-
tion (EMT) in advanced cancer [28]. However, activin’s
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Fig. 2 Activin but not TGFβ utilizes PI3K/Akt to downregulate p21 in a SMAD4-independent manner. a Activin but not TGFβ leads to PI3K
activation in a SMAD4-independent manner. ACVR2A/TGFBR2 wild type FET cells, FET with SMAD4 knockdown, and the SMAD4-null colon
cancer cell line SW480 were stimulated with activin or TGFβ for 24 h following serum starvation. pAkt level was determined by Western
Blot. Akt was used as a loading control. pAkt increased after cells were treated with activin but not TGFβ. b ACVR1B, ACVR2A’s primary
binding partner, interacts with p85, the regulatory subunit of PI3K in an activin-dependent manner. Co-immunoprecipitation (Co-IP) with
ACVR2A/TGFBR2 wild type FET cells were used to detect a protein-protein interaction between ACVR1B and p85. c p21 downregulation is
dependent on Akt, a PI3K downstream target. ACVR2A/TGFBR2 wild type FET cells were transfected with siRNA to Akt1/2 (KD) and treated
with activin or TGFβ for 24 h following serum starvation. Activin-induced downregulation of p21 was abrogated after Akt1/2 knockdown
implicating Akt in activin-induced p21 regulation. d Knock down of downstream target in FET cell. ACVR2A/TGFBR2 wild type FET cells were
transfected with siRNA Akt1/2 and siRNA SMAD4. Resulting loss of respective protein expression is shown using Western blotting. For siRNA
SMAD4 we tested two different siRNA from Ambion (A: middle panel) and Santa Cruz (SC: right panel) and the latter was used in all our
experiments. (C control; A Activin; T TGFβ; KD siRNA Akt1/2; IP immunoprecipitation)
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effects on EMTare currently unclear. As activin downre-
gulates p21 and accordingly opposes EMT in breast
cancer [29], we assessed the potential contribution of
activin and its downstream signaling to EMT in colon
cancer. For this, FET cells were treated with either acti-
vin or TGFβ, and expression of E-Cadherin (epithelial
phenotype) and vimentin (mesenchymal phenotype)
were determined after 24 h, 72 h and 1 week. Seventy-
two hours and 1 week after TGFβ or activin treatment,
E-Cadherin expression was reduced compared to con-
trols while vimentin expression was increased (Fig. 5a),
consistent with EMT. Treatment with TGFβ led to an
increase in p21 at 24 h, which was not sustained at longer
time points. However, the activin-induced downregulation
of p21 was stable over time (Fig. 5a). This is consistent
with our previous data suggesting that activin may be a
more potent inducer of migration [9], as in cells with
intact SMAD4, TGFβ induced p21 may counteract
migration [9] and EMT at early time points.
As we observed that pERK plays a role in phos-
phorylation of SMAD2 (Fig. 3), we next assessed the
role of MEK/pSMAD2 or PI3K in TGFβ or activin-
A BFET
0
1
2
3
4
******
ra
tio
 G
AP
D
H
/p
21
0
1
2
3
4
*
*
ra
tio
 G
A
P
D
H
/p
21
0
1
2
3
4 *
**
ra
tio
 G
A
P
D
H
/p
21
0
1
2
3
4
ra
tio
 G
A
P
D
H
/p
21
p21
GAPDH
FET SMAD4 KD
A A+U A+LY CC T T+U T+LY
SW480
C CA A+U A+LY T+U T+LYT
p21
GAPDH
C
C T+U T+LYT
pSMAD2
FET
GAPDH
0
1
2
3
4
ra
tio
 G
AP
D
H
/p
21
0
1
2
3
4 *
***
ra
tio
 G
AP
D
H
/p
21
0
2
4
6
8
10
12
pERK1 ppERK1pERK2 ppERK2
*** *** * *
*** ** **
**
fo
ld
 in
cr
ea
se
C CC ACA A AT T T T
C A A+U A+LY
p21
GAPDH
Fig. 3 TGFβ but not activin stabilizes p21 via SMAD4 and MEK/ERK. a TGFβ-induced p21 upregulation is MEK/ERK dependent and not influenced by
PI3K inhibition. In contrast, activin-induced p21 downregulation is dependent on PI3K signaling, but not dependent on SMAD4. ACVR2A/TGFBR2 wild
type FET cells, FET with SMAD4 knockdown, and the SMAD4-null colon cancer cell line SW480 were treated with activin or TGFβ for 24 h 30 min after
pharmacologic inhibition of PI3K (LY 290042) or MEK1/2 inhibition (U0126) and p21 levels determined by Western blot. GAPDH was used as a loading
control. Three independent experiments entered the densitometric analysis shown below the representative blots (*p < 0.05, **p < 0.01, ***p < 0.001).
For simplicity, we only show level of significance between control versus activin; control versus TGFβ; and activin versus LY and TGFβ versus U. b TGFβ
treatment prominently increases the phosphorylation of ERK1/2 in colon cancer cells. Isoelectric point immunoassay was performed in FET cells treated
with activin or TGFβ and pERK1/2 and ppERK1/2 compared to vehicle control. Five independent experiments were performed (*p < 0.05, **p < 0.01,
***p < 0.001). c TGFβ utilizes MEK/ERK to induce pSMAD2. ACVR2A/TGFBR2 wild type FET cells were treated with activin, TGFβ or vehicle control for
24 h following pretreatment with PI3K and MEK/ERK inhibition. pSMAD2 was determined by Western blot analysis and GAPDH was used as a loading
control. Activin-induced pSMAD2 increase is independent from PI3K and MEK/ERK, but inhibition of MEK/ERK abolishes TGFβ-induced upregulation of
pSMAD2 (A + LY Activin + LY; A + U Activin + U0126; T + LY TGFβ + LY; T + U TGFβ + U0126)
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mediated EMT. Phosphorylation of ERK and SMAD2
increased after TGFβ treatment relative to control at all
the time points examined (Fig. 5a). Further, concomitant
inhibition of PI3K led to a downregulation of activin-
induced EMT while inhibition of MEK led to a decrease of
EMT after TGFβ treatment evident through changes in
E-Cadherin and vimentin expression (Fig. 5b). Taken
together, despite their shared regulation of SMAD
signaling, activin and TGFβ diverge in their down-
stream signaling to affect induction of an invasive
phenotype in colon cancer.
Loss of ACVR2A in vivo is associated with pAkt down
regulation in intestinal tumors
To explore the mechanisms through which activin
affects PI3K signaling in vivo, ACVR2A knockout mice
(KO) and ACVR2A control wild type (wt) mice were
used in a murine model of colitis-associated colorectal
cancer. While there was a trend towards more intes-
tinal cancers in the challenged ACVR2A knock outs
compared to wild type mice, this was not statistically
significant, underscoring the likely overlap/synergy of
TGFβ family member signaling in colon cancer (Fig. 6).
We then isolated tumor tissues and paired normal
tissues from the colons of study animals to quantify
pAkt (Ser 473), pan Akt and p21 expression. The level of
pan Akt was similar across mice (Fig. 6). However, in
tumor tissue of ACVR2A KO mice, we observed a decrease
in pAkt and an increase in p21 compared to normal tissue
(Fig. 6b right panel) consistent with an activin/PI3K/Akt
involvement in p21 downregulation in colon cancer. An
increase of p21 and a decrease in pAKT in the tumor
tissue of ACVR2A KO mice is significant (Fig. 6c).
In summary, we show differential and parallel acti-
vin and TGFβ signaling in colon cancer. These path-
ways involve both SMAD4-dependent and independent
signaling cascades and utilize distinct mitogenic signaling
effectors (Fig. 7). Both TGFβ and activin may signal via
SMADs to upregulate p21 at early time points [9]. In
colon cancer, this pathway is non-dominant [9] and
activin preferentially downregulates p21 via PI3K/Akt
in a SMAD4-independent fashion. This is associated
with an increase in metastatic phenotype as evidenced by
increased migration and EMT. In addition, loss of nuclear
p21 correlates with activin/PI3K signaling activation in
primary colon cancers, however, some cancers retain net
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Fig. 4 Activin and TGFβ use distinct mitogenic signaling to affect SMAD4- independent migration. Activin and TGFβ are both inducers
of migration independent of SMAD4. ACVR2A/TGFBR2 wild type FET cells, FET with SMAD4 knockdown, and the SMAD4-null colon cancer
cell line SW480 were seeded in transwell plates, serum starved, and pretreated with pharmacological inhibitors of PI3K (LY 290042) or
MEK (U0126). Activin and TGFβ-induced migration is SMAD4-independent. Activin-induced migration is decreased in the absence of PI3K
signaling and TGFβ-induced migration is MEK/ERK dependent. Inserts show representative fields with migrated FET cells. Graph shows
data from 4 independently performed experiments (*p < 0.05 Activin versus Activin + LY; #p < 0.05 TGFβ versus TGFβ + U0126)
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nuclear p21, suggestive of dominant growth suppres-
sive TGFβ/SMAD signaling. These data suggest further
validation of nuclear p21 as a therapeutic biomarker, and
indicate caution should be exercised when inhibiting TGFβ
signaling in colon cancers with retained nuclear p21.
Discussion
TGFBR2 and ACVR2A are commonly mutated in micro-
satellite unstable (MSI) colon cancers, which is the second
most common genomic subtype [30]. The characteristic
defects in mismatch repair result in mutations in
repetitive sequences termed microsatellites [31–34].
Both TGFBR2 and ACVR2A harbor coding microsa-
tellites and mutations in MSI colon cancers which
are associated with loss of protein expression [35]. In
addition, mutations in non-MSI cancers may occur in
their common downstream signaling component SMAD4
[3]. While all this underscores that the TGFβ super-
family undoubtedly is important in colon cancer, the
respective contribution of each pathway is still poorly
understood. Detailing such contributions and func-
tional net effects in colon cancer is crucial when
envisioning treatment with the now emerging TGFβ
pathway inhibitors.
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Fig. 5 Activin and TGFβ induce epithelial to mesenchymal transition via distinct mitogenic signaling and downregulation of p21. a Both TGFβ
and activin treatment induce a decrease of E-Cadherin and an increase in vimentin, indicative of EMT while p21 is downregulated. TGFβ-induced
p21 upregulation normalizes over time while activin induced downregulation of p21 persists. ACVR2AsTGFBR2 wild type FET colon cancer cells
were treated with activin or TGFβ and lysed after 24 h, 72 h or 1 week, respectively. EMT was determined using E-Cadherin as an epithelial and
vimentin as a mesenchymal marker. p21, pERK, pSMAD2 during activin and TGFβ-induced EMT were also interrogated. Phosphorylation of SMAD2
and ERK increased over time after TGFβ treatment. b Inhibition of PI3K following activin and inhibition of MEK following TGFβ treatment leads to
a decrease in EMT. FET cells were pretreated with PI3K (LY 290042) or MEK (U0126) prior to stimulation with activin or TGFβ and lysed after one
week. EMT was determined using E-Cadherin as an epithelial marker. Representative blots of 3 independent experiments are shown
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It is conceivable that the redundancy in down-
stream SMAD signaling as exhibited by activin and
TGFβ may lead to pathway rescue [36]; however, given the
complex cross talk between TGFβ family members and
other signaling pathways, this is likely an oversimplifica-
tion. We and others have found SMAD-independent
signaling is associated with distinct functional effects
that occur parallel to SMAD signaling in SMAD4 wild
type colon cancer cells [9]. In addition, when both
signaling cascades are intact, there is downstream
divergence in the regulation of p21 [9], which may
remain dominant in some cancers and underscores
the complexity of pathway interactions.
It is clear that TGFβ family signaling is modified
dependent on cellular context [3]. Parallel signaling
of TGFβ and activin likely both play a role in the
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Fig. 6 Loss of ACVR2A in vivo is associated with pAkt downregulation in intestinal tumors. Loss of ACVR2A leads to pAkt downregulation and p21
upregulation in ACVR2A knockout KO mice. ACVR2A wild type (wt) and ACVR2A KO mice were used in a DSS/AOM intestinal cancer model. Mice were
injected intraperitoneally with AOM and after 5 days were given 3 cycles of DSS. Lysates from normal (a) and 10.1186/s12943-015-0456-4 intestinal
tumor tissue (b) were probed for p21, pan-Akt, and pAkt expression via Western blot. Tumor and normal tissue from four different mice from each
group of ACVR2A wt and ACVR2A KO mice is shown. c Loss of ACVR2A is associated with a decrease in pAkt and an increase of p21, which is most
pronounced in intestinal tumor tissue. Immunobloy signal was quantified by densitometry and the ratio of p21 to pAKT expression was determined
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development of advanced colon cancer, and net signal-
ing will be affected by selective pathway abrogation as
a result of the mutational heterogeneity of each tumor.
Understanding this net signaling effect is crucial to the
development of therapeutic approaches which target the
pro-migratory function in advanced colon cancer while
protecting the anti-proliferative functions of TGFβ in early
colorectal cancer development. In this report, we have
dissected activin and TGFβ signaling divergence and their
net functional effects with the aim of identifying a poten-
tial therapeutic marker.
Colon cancer treatment is entering the realm of
precision medicine. Metastatic colon cancers are rou-
tinely tested for mutant KRAS to determine suitability for
biologic adjuvant therapy with the anti-epidermal growth
factor receptor (EGFR) antibody, cetuximab [37], as sur-
prisingly, patients with mutant KRAS fared worse with
anti-EGFR therapy than without treatment [37]. Small
molecule inhibitors for both TGFBR1/2 and ACVR1B
are available and conceivably could be used as adjuvant
therapies in advanced colon cancer, but biomarkers to
determine treatment suitability and specifically to avoid
augmentation of oncogenic signaling are lacking. This
need is underscored by a recent report that in pancre-
atic cancer inactivation of PI3K/mTOR signaling led to
compensatory increase in mitogenic MEK/ERK signal-
ing [38]. Here, we have dissected signaling overlap and
divergence of activin and TGFβ signaling as well as
respective mitogenic signaling and we now suggest
nuclear p21 expression as a potential read out for active
upstream growth suppressive TGFβ/SMAD signaling.
Further, we caution that inhibition of TGFβ in such
cancers may lead to increased growth.
Mitogenic signaling pathways are frequently acti-
vated in cancers and the subject of intense investiga-
tion for therapeutic intervention. The MAPK pathway
is commonly activated in tumors by direct mutation or
overexpression of upstream molecules such as BCR-
ABL and EGFR. TGFβ can activate MAPK and PI3K
dependent on cell type and culture condition [3, 39].
We now observe that in colon cancer cells MAPK is
activated by TGFβ by a SMAD-dependent mechanism
leading to regulation of p21 expression.
In contrast, we also report that PI3K is an active signal-
ing component of activin/SMAD-independent mediated
downregulation of p21 and associated with a metastatic
phenotype. Consistent with an activin/PI3K/pAkt–induced
p21 downregulation, we now show that in colon tumors of
ACVR2A KO mice pAkt activation is diminished and p21
levels are restored. Activation of PI3K is a potential
mechanism of resistance to various cancer therapies
[24, 26, 40] and when constitutively activated, thera-
peutic targeting of PI3K may be beneficial. In breast
cancer cells, for instance, Akt may decrease p21 expression
ACVR2 ACVR2       ACVR1
Activin
pSMAD2
TGFBR1 1RBFGT2RBFGT
TGFβ
TGFBR2
p21
SMAD4
Migration/EMT
PI3K
p21
Migration/EMT
p85
pSMAD2
SMAD4
p21
ACVR1
pERK pAKT
Fig. 7 Parallel activin and TGFβ signaling in advanced colon cancer. TGFβ and activin both share SMAD4 signaling to upregulate p21.
However, in colon cancer, there is ligand-specific SMAD4-independent signaling utilizing distinct mitogenic signaling. Moreover, activin
dominantly induces downregulation of p21 via PI3K/Akt signaling over early SMAD4-dependent p21 upregulation in colon cancer (non-dominant
pathway indicated in grey). Net nuclear p21 expression in colon cancer may be a functional surrogate of intact TGFβ/SMAD growth suppression and a
negative possible predictor of growth enhancing response to TGFβ pathway inhibition. In contrast, colon cancers with loss of nuclear p21 may benefit
from activin, TGFβ or combination inhibitory therapy. In summary, there is complex parallel signaling with feedback loops operative in colon cancer
downstream of activin and TGFβ. In order to predict net functional effects of targeted pathway disruption on tumor behavior, it is crucial that the
interplay of pathways is fully appreciated to minimize unwanted side effects
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[41] enhancing to oncogenic behavior [42], which is
consistent with our data regarding activin/PI3K/p21
downregulation.
p21 is a member of the Cip and Kip family of Cdk
inhibitors, which includes p21, p27, and p57 [43].
These inhibit the kinase activity of broad, but not
identical, classes of Cdk-cyclin complexes through
their N-terminal homologous sequences. p21 arrests
cell cycle progression primarily through the inhibition of
Cdk2 activity, though it can also mediate p53-dependent
G1 growth arrest. Earlier studies support the view that
p21 suppresses tumors by promoting cell cycle arrest in
response to various stimuli [44, 45]. While p21 regulation
is often compromised in human cancers, its continuous
expression, depending on the cellular context, suggests
that it can act as either a tumor suppressor or an onco-
gene [43]. Deletion of p21 enhanced the rate of Ras- or
c-Myc-induced tumorigenesis, and was associated with
gene expression profiles and immunohistochemical fea-
tures of EMT [29], consistent with our finding of enhanced
migration with activin-induced p21 downregulation. Simi-
larly, the loss of p21 enhanced the baseline total migration
as well as activin-induced migration in SMAD4 intact cells,
[9]. TGFβ induced p21 upregulation is decreasing over
time and associated EMT.
As EMT is a central process in normal development,
reactivation in cancer is regarded as dedifferentiation.
It is typically characterized by the loss of cell-cell adhe-
sion and apical-basal polarity, and may be induced by
many different signaling pathways including TGFβ
[20]. EMT manifests with repression of E-Cadherin
often via Snail genes, and the development of a fibroblast-
like motile phenotype [28]. Both SMAD-dependent and
SMAD-independent signaling originating from TGFβ
receptors have been implicated [3]. Context-dependent
enhancement of EMT by additional mechanisms can
include PI3K activation [46], as well as PDGF, EGF, and
VEGF [20]. The molecular switch of TGFβ from tumor
suppressive to oncogenic is also likely context-dependent,
but remains poorly understood. We have previously
reported a switch similar to that of TGFβ for activin sig-
naling [9] and now show data implicating activin in EMT
as well. TGFβ-induced EMT has been studied in detail
but not much is known about the impact of activin signal-
ing. There are some data that suggest that activin does not
lead to EMT [18] or has a low impact on EMT [17], but
experimental approaches were varied. Ansieau et al.
report that Twist inhibits p21 leading to EMT and
inhibition of oncogene-induced senescence [47] and
our data suggests that TGFβ induced upregulation of
p21 is decreasing over time in conjunction with increased
EMT. Data from Barrallo-Gimeno et al. suggest long term
exposure to TGFβ favors EMT over growth suppression
[48], corresponding to our observations. Similarly, we
show that while TGFβ increases p21 expression
acutely [9], long term exposure (72 h and one week
respectively) in colon cancer cells leads to downregu-
lation by activin or loss of upregulation by TGFβ of
p21 and subsequent induction of cell migration and
EMT. We have previously reported that the down-
regulation of p21 leads to an increase of migration
[9]. Our current data suggests a correlation between
the downregulation of p21 and an increase in EMT.
Small molecule inhibitors directed at growth factor
receptors (such as EGFR) may interfere with EMT,
although independent of primary receptor expression
[20]. To forestall the development of autocrine loops,
neutralizing antibodies against TGFβ ligand as well
as combination therapy directed against EGFR and
PI3K are being assessed [20].
Conclusion
Understanding the complex molecular networks oper-
ating in cancer EMT is of utmost importance in the
development of much needed biomarkers for risk and
treatment stratification and for developing targeted
combination therapies in advanced colon cancer. TGFβ
and activin are prometastatic ligands in colon cancer
which regulate EMT. These signaling molecules use
identical upstream signaling that diverge at p21. Here,
we show that activin and TGFβ actions in colon cancer
are complex and involve distinct downstream mitogenic
signaling. We further suggest that tumoral nuclear p21
may predict intact growth suppressive TGFβ signaling
and may need to be assessed before planning trials with
inhibition of TGFβ family pathways.
Material and methods
Colon cancer cell lines
SW480 (ATCC, Manassas, VA, USA) were main-
tained in DMEM, and FET cells (gift from Michael
Brattain, University of Nebraska, Omaha, NE, USA)
were maintained in DMEM/F12 50:50 (both Corning,
Corning, NY, USA) supplemented with 10 % fetal
bovine serum and penicillin (100 U/ml)/streptomycin
(100 μg/ml) (Invitrogen, Carlsbad, CA, USA). Cells
were grown at 37 °C in a humidified incubator with
5 % CO2. All cells were serum starved for 24 h prior to
treatment to approximate cell cycle synchronization. Cells
were validated by 9 STR (short tandem repeat) profiling
using CellCheck 9 Plus and tested for mycoplasma (both
IDEXX, Columbia, MO, USA).
Reagents and antibodies
Activin A was reconstituted in PBS; TGFβ1 in 4 mM
HCl according to the manufacturer’s instruction (both
R&D, Minneapolis, MN, USA). Final concentrations used
were 25 ng/ml and 10 ng/ml, respectively, as previously
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described [31, 49–51]. For inhibition of PI3K, we used
LY294002 and for inhibition of MEK1/2, U0126 (both
Cell Signaling Technology, Danvers, MA, USA). For
immunoprecipitation and Western blotting, we used anti-
bodies against ACVR1B (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), ACVR2A (customized by Yenzym, San
Francisco, CA, USA), p85 (# 4292), TGFBR1 (# 3712) or
TGFBR2 (# 3713, all Cell Signaling), p21 (# sc-65595,
Santa Cruz), pan-Akt (# 8805, Abcam, Cambridge, MA,
USA), GAPDH (# sc-47724, Santa Cruz), E-Cadherin (#
3195), vimentin (# 3390), pAkt Ser473 (# 4060) and pAkt
Thr308 (# 13842, all Cell Signaling). For immunohisto-
chemical analyses, we used p21 (# sc-817, Santa Cruz)
ACVR2A (# ab10595), TGFBR2 (# ab78419), pAkt Ser473
(# ab81283, abcam), and pERK1/2 (# ab50011, all Abcam).
Western blotting
Cells were lysed using CHAPS lysis buffer (containing
20 mM Bicine pH 7.6 and 0.6 % Chaps) with added pro-
tease and phosphatase inhibitors. Western blots were
performed as previously described [9].
siRNA and transfection
siRNA for SMAD4 (Ambion and Santa Cruz) and Akt1/
2 (Santa Cruz) were transfected at a final concentration
of 10 nM via electroporation using the AMAXA Nucleo-
fector (Lonza, Basel, Switzerland) in 6-well plates at a
density of 1×106 per well according to the manufac-
turer’s instructions. Transfection efficiency was con-
firmed using the pmaxGFP™ Control Vector. Forty-eight
hours post transfection, colon cancer cells were lysed for
protein extraction.
Migration assay
Migration assays were performed as previously described
[31]. Briefly, transwell 12 well plates (8 μm pores,
Corning, NY, USA) with fibronectin (Sigma, St. Louis,
MO, USA) were seeded with 5 × 105 colon cancer
cells per well. Cells were then allowed to migrate for
6 h, stained, and imaged. Images from 5 microscopic
fields at the center of each well were counted.
Patient samples
110 colon cancer and adjacent normal tissue stains (fixed
in formalin and embedded in paraffin) were obtained from
Northwestern Memorial Hospital as de-identified, archived
tissue samples under IRB approval. Additional File 4: Table
S1 contains individual patient information. Gender, age,
tumor stage and expression of p21, TGFBR2 and ACVR2
is listed for each patient analyzed.
Immunohistochemistry
Slides containing primary colon cancer and normal tis-
sues were processed as previously described [52] and
stained for AVCR2, TGFBR2, p21, pERK, and pAkt
using the Catalyzed Signal Amplification System (CSA)
by DAKO (Carpinteria, CA, USA). ACVR2A, TGFBR2,
pERK, and pAkt staining was grouped into negative
(no or weak signal) and positive (moderate or strong
signal) status. The percentage of p21 positive nuclei in
each cancer sample was assessed. p21 staining was
grouped into nuclear (>50 % nuclei positive) or loss of
nuclear (<50 % of nuclei positive). Slides were scored
blindly by two investigators.
Immunoprecipitation
1 mg of total protein lysate from various treatments
were incubated with 1 μg of ACVR1B or ACVR2A anti-
body (Yenzym); ligand specificity was confirmed with
TGFBR1 or TGFBR2 (Cell Signaling) overnight at 4 °C.
Protein A beads (Invitrogen, Carlsbad, CA, USA) were
added for 6 h. After denaturation with sample buffer,
equivalent protein was fractionated on 4-20 % gradient
gels (Biorad, Hercules, CA, USA), transferred to mem-
branes and blotted with antibodies against ACVR1B
antibody (Santa Cruz), and p85 (Cell Signaling).
ACVR2A KO in vivo mouse tumor model
ACVR2A KO and ACVR2A wild type (wt) mice were
treated with 14 mg/kg Azoxymethane (AOM) intraperi-
toneal infusion. After 5 days, mice were treated with
3 cycles of 2.5 % dextran sulfate sodium (DSS). Every
cycle contained 5 days of DSS and 15 days of water.
After day 100, the mice were sacrificed. Tumor and nor-
mal tissues were collected and lysed in RIPA buffer (1 %
NP-40, 0.1 % SDS, 50 mM Tris–HCl pH 7.4, 150 mM
NaCl, 0.5 % Sodium Deoxycholate, 1 mM EDTA) prior
to use in Western blot analysis.
Isoelectric focusing immunoassay
Detection of ERK1/2 phosphoisoforms after TGFβ and
activin treatment was achieved using an automated
capillary based isoelectric focusing immunoassay sys-
tem (NanoPro1000 assay, ProteinSimple, Santa Clara,
CA, USA). Protein isolation, detection, and quantifica-
tion were done as per the manufacturer’s instructions.
In brief, FET colon cancer cells were lysed in CHAPS
buffer and 0.2 μg/ml protein was plated in a 384 well
plate. For the primary antibody, we used pERK1/2 and
ERK1/2 (Cell Signaling) diluted at 1:100. Luminescence
and fluorescence images were collected using a charge-
couple device (CCD) camera. Peak integration and isoelec-
tric point (pI) marker calibration (for peak alignment) were
performed using Compass, version 1.3.7, software (Protein
Simple). The difference of isoform expression after TGFβ
and activin treatment was compared to the vehicle control.
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Statistical analysis
Differences between groups were determined using
the Student’s t-test. Probability values less than 0.05
were considered significant. Biological replicates from
3–5 experiments represent the data shown. For associa-
tions of IHC staining patterns, we performed Fisher’s
exact test calculations.
Additional files
Additional file 1: Table S2. Correlation of signaling pathway
expression in primary colon cancer slides.(DOCX 73 kb)
Additional file 2: Figure S1. ACVR2 interacts with p85 after activin
treatment. FET cells were used for co-immunoprecipitation with ACVR2,
TGFBR1 or TGFBR2 and Western blotted with p85. There is an induction
of ACVR2/p85 association following activin treatment, however, the in-
crease in ACVR1/p85 association was more pronounced. Neither TGFBR1
nor TGFBR2 directly associated with p85 following ligand stimulation.
(EPS 3051 kb)
Additional file 3: Figure S2. Activin-induced migration is reglated via
PI3K and TGFbeta induced migration via MEK/ERK, both independent of
SMAD4. Migration assays with FET cell lines were performed after 6 hours
of ligand incubation and cells were compared by counting nuclei,
stained blue with DAPI. (EPS 5130 kb)
Additional file 4: Table S1. Characteristics of colon cancer patient
cohort randomly selected from Northwestern University for p21, TGFBR2,
ACVR2, pERK, and pAkt staining. Ten patients did not have stage
information available (X). (DOC 170 kb)
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